Tomisa G - Search Results

1

Changes in the Burden of Comorbidities in Patients with COPD and Asthma-COPD Overlap According to the GOLD 2017 Recommendations.

Bikov A, Horváth A, Tomisa G, Bártfai L, Bártfai Z. Bikov A, et al. Among authors: tomisa g. Lung. 2018 Oct;196(5):591-599. doi: 10.1007/s00408-018-0141-7. Epub 2018 Jul 14. Lung. 2018. PMID: 30008015

2

Computer modeling of airway deposition distribution of Foster(®) NEXThaler(®) and Seretide(®) Diskus(®) dry powder combination drugs.

Jókay Á, Farkas Á, Füri P, Horváth A, Tomisa G, Balásházy I. Jókay Á, et al. Among authors: tomisa g. Eur J Pharm Sci. 2016 Jun 10;88:210-8. doi: 10.1016/j.ejps.2016.03.008. Epub 2016 Mar 11. Eur J Pharm Sci. 2016. PMID: 26976481

3

Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.

Farkas Á, Jókay Á, Balásházy I, Füri P, Müller V, Tomisa G, Horváth A. Farkas Á, et al. Among authors: tomisa g. Eur J Pharm Sci. 2016 Oct 10;93:371-9. doi: 10.1016/j.ejps.2016.08.036. Epub 2016 Aug 21. Eur J Pharm Sci. 2016. PMID: 27552906

4

Characteristics of an optimized patient information material for elderly patients with obstructive pulmonary diseases based on patients' and experts' assessment.

Tomisa G, Horváth A, Dombai B, Tamási L. Tomisa G, et al. Multidiscip Respir Med. 2017 Mar 14;12:6. doi: 10.1186/s40248-017-0087-2. eCollection 2017. Multidiscip Respir Med. 2017. PMID: 28316784 Free PMC article.

5

Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients.

Horváth A, Balásházy I, Tomisa G, Farkas Á. Horváth A, et al. Among authors: tomisa g. Eur J Pharm Sci. 2017 Jun 15;104:145-149. doi: 10.1016/j.ejps.2017.03.047. Epub 2017 Apr 4. Eur J Pharm Sci. 2017. PMID: 28389274

6

Effect of delayed pMDI actuation on the lung deposition of a fixed-dose combination aerosol drug.

Farkas Á, Horváth A, Kerekes A, Nagy A, Kugler S, Tamási L, Tomisa G. Farkas Á, et al. Among authors: tomisa g. Int J Pharm. 2018 Aug 25;547(1-2):480-488. doi: 10.1016/j.ijpharm.2018.06.016. Epub 2018 Jun 7. Int J Pharm. 2018. PMID: 29886099

7

Prevalence and impact of risk factors for poor asthma outcomes in a large, specialist-managed patient cohort: a real-life study.

Tomisa G, Horváth A, Szalai Z, Müller V, Tamási L. Tomisa G, et al. J Asthma Allergy. 2019 Sep 23;12:297-307. doi: 10.2147/JAA.S211246. eCollection 2019. J Asthma Allergy. 2019. PMID: 31576150 Free PMC article.

8

Impact of Clinical Factors on Generic and Disease-Specific Quality of Life in COPD and Asthma-COPD Overlap with Exacerbations.

Lázár Z, Horváth A, Tomisa G, Tamási L, Müller V. Lázár Z, et al. Among authors: tomisa g. Pulm Med. 2020 Jun 25;2020:6164343. doi: 10.1155/2020/6164343. eCollection 2020. Pulm Med. 2020. PMID: 32789027 Free PMC article.

9

Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.

Horváth A, Farkas Á, Szipőcs A, Tomisa G, Szalai Z, Gálffy G. Horváth A, et al. Among authors: tomisa g. Eur J Pharm Sci. 2020 Nov 1;154:105508. doi: 10.1016/j.ejps.2020.105508. Epub 2020 Aug 21. Eur J Pharm Sci. 2020. PMID: 32836137 Free article.

10

[Health effects of cigarettes, electronic cigarettes and waterpipes].

Farkas Á, Tomisa G, Kis E, Horváth A. Farkas Á, et al. Among authors: tomisa g. Orv Hetil. 2021 Jan 17;162(3):83-90. doi: 10.1556/650.2021.32079. Orv Hetil. 2021. PMID: 33459608 Hungarian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters